TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01008527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 870,893
Description: Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptides
Description: NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncovir poly IC:LC
Description: The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
Study: NCT03994952

Intervention type: DEVICE
Intervention: Sway Balance Application
Description: Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.

Intervention type: DEVICE
Intervention: Balance Tracking Systems
Description: This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
Study: NCT02363127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous progesterone
Description: subcutaneous progesterone 25 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: vaginal progesterone in capsules 200 mg/3 times a day
Study: NCT00348374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exubera
Description: Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
Study: NCT00752362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Milennium Matrix® (Control)
Description: Percutaneous coronary intervention with bare metal stent
Study: NCT00799461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management
Description: Assessing and managing fatigue

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: fatigue assessment and management
Description: Assessing and managing fatigue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Counseling provided via telephone
Study: NCT03569917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rectal swab collection
Description: Rectab swab collection will be performed at inclusion and 5 and 30 days later.
Study: NCT01423903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-51602
Description: A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
Study: NCT00752362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infinnium®
Description: Percutaneous coronary intervention with paclitaxel-eluting stent
Study: NCT02988375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBTI

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education
Study: NCT00752362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supralimus®
Description: Percutaneous coronary intervention with sirolimus-eluting stent
Study: NCT04343768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms.
Study: NCT02046122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLI
Description: HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10\^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation.
Study: NCT00397657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extended release niacin
Description: Extended release niacin will be started at 1000mg and titrated to 2000mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: Ezetimibe 10mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: Ezetimibe 10mg once daily
Study: NCT03795441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Description: Ad26.RSV.preF will be administered as intramuscular injection on Day 1.
Study: NCT03835845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO7Y
Description: The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
Study: NCT01371617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-926
Description: Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
Study: NCT04343768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir / Ritonavir
Description: This Drug will be used in all arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1A
Description: This drug will be only used in Arm 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1B
Description: This drug will be only used in Arm 2.
Study: NCT04004208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea (Aflibercept, BAY86-5321)
Description: Solution in a sterile glass vial, Dose A, IVT injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Transpupillary conventional laser ablative therapy
Study: NCT00265005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alteplase
Description: Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
Study: NCT02898675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrine
Description: Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Debridement
Description: Only open flap debridement treatment the bone loss limitedly
Study: NCT05051410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracanal cryotherapy using needle irrigation and EndoVac system
Description: a cold saline will be used as final irrigant in two groups but with different irrigation systems.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracanal cryotherapy using needle irrigation and EndoVac system
Description: a cold saline will be used as final irrigant in two groups but with different irrigation systems.
Study: NCT05653011

Intervention type: OTHER
Intervention: Endoscopic biopsy
Description: When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions.

Intervention type: OTHER
Intervention: Endoscopic biopsy
Description: When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions.

Intervention type: OTHER
Intervention: Endoscopic biopsy
Description: When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions.
Study: NCT02046876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physiotherapy Program
Description: Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
Study: NCT02715856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Undergo surgical wound and physical activity monitoring
Study: NCT01458249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
Study: NCT02715856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Measurement
Description: Undergo physical activity measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Measurement
Description: Undergo physical activity measurement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Undergo standard follow-up care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Follow-Up Care
Description: Undergo standard follow-up care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03958097

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NK cell and PD-1 antibody
Description: Each patient enrolled the study will received both NK cell and PD-1 antibody.
Study: NCT02206438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of C-LMA
Description: After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of air-Q according
Description: After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
Study: NCT01682603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: BoNT-A (BOTOX 300U)
Study: NCT02505672

Intervention type: RADIATION
Intervention: Chemoradiotherapy for nasopharyngeal carcinoma
Description: Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
Study: NCT04843839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1% Oph Susp
Description: Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Tears 0.5% Lubricant Eye Drops
Description: Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
Study: NCT04125719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Intralesional injection of PVSRIPO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Intralesional injection of PVSRIPO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab infusion
Study: NCT03351959

Intervention type: RADIATION
Intervention: neo-adjuvant treatment
Description: long-course radio-chemoradiation; short-course radiation with immediate/delayed surgery
Study: NCT02242903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3079514
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3079514
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT05084885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online therapy
Description: Standard counseling provided over the internet.
Study: NCT04691596

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App use instructions
Description: Received a basic training with the StepUp app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App use instructions
Description: Received a basic training with the StepUp app
Study: NCT06002594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group low-volume irrigation
Description: Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 4 ml of 0.9% sodium chloride(NaCl) solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group high-volume irrigation
Description: Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 20 ml of 0.9% NaCl solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
Study: NCT02124421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive Surgery (CRS)
Description: Cytoreductive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery (CRS)
Description: Cytoreductive surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
Study: NCT01359098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex Otic Suspension
Description: 4 gtt b.i.d. for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprodexa Otic Foam
Description: 0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
Study: NCT04075981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection [Xeomin]
Description: Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drug placebo
Description: All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
Study: NCT04691596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App use instructions
Description: Received a basic training with the StepUp app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App use instructions
Description: Received a basic training with the StepUp app
Study: NCT00433654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: One hour MRI scan on the head and lower back.
Study: NCT01424202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation Exsufflation
Description: After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse.
Study: NCT04394182

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-Low-dose radiotherapy
Description: The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
Study: NCT02124421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy
Description: Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
Study: NCT04394182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilatory support with oxygen therapy
Description: Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
Study: NCT00825448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hospitalization for a week
Description: Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)